{"eventGroups":[{"deathsNumAffected":1,"deathsNumAtRisk":3,"description":"3Gy with standard high dose melphalan prior to autologous stem cell rescue\n\nTotal Marrow Irradiation: Subjects in this trial will receive total marrow irradiation 3Gy per day for up to four days and as little as one day\n\nMelphalan: Subjects will receive standard melphalan 200mg/m\\^2 (100mg/m\\^2 day-2 and day-1) conditioning therapy prior to transplant\n\nFilgrastim (G-CSF): Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC \\> 1000/mm\\^3 over period of 3 days.\n\nAutologous transplant: Subjects will receive standard melphalan 200mg/m\\^2 (100mg/m\\^2 day-2 and day-1) conditioning with autologous stem cell rescue","id":"EG000","otherNumAffected":2,"otherNumAtRisk":3,"seriousNumAffected":1,"seriousNumAtRisk":3,"title":"Cohort 1Total Marrow Irradiation (TMI) 3Gy"},{"deathsNumAffected":1,"deathsNumAtRisk":3,"description":"6Gy with standard high dose melphalan prior to autologous stem cell rescue\n\nTotal Marrow Irradiation: Subjects in this trial will receive total marrow irradiation 6Gy per day for up to four days and as little as one day\n\nMelphalan: Subjects will receive standard melphalan 200mg/m\\^2 (100mg/m\\^2 day-2 and day-1) conditioning therapy prior to transplant\n\nFilgrastim (G-CSF): Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC \\> 1000/mm\\^3 over period of 3 days\n\nAutologous transplant: Subjects will receive standard melphalan 200mg/m\\^2 (100mg/m\\^2 day-2 and day-1) conditioning with autologous stem cell rescue","id":"EG001","otherNumAffected":2,"otherNumAtRisk":3,"seriousNumAffected":1,"seriousNumAtRisk":3,"title":"Cohort 2 Total Marrow Irradiation (TMI) 6Gy"},{"deathsNumAffected":1,"deathsNumAtRisk":6,"description":"9Gy with standard high dose melphalan prior to autologous stem cell rescue\n\nTotal Marrow Irradiation: Subjects in this trial will receive total marrow irradiation 9Gy per day for up to four days and as little as one day\n\nMelphalan: Subjects will receive standard melphalan 200mg/m\\^2 (100mg/m\\^2 day-2 and day-1) conditioning therapy prior to transplant\n\nFilgrastim (G-CSF): Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC \\> 1000/mm\\^3 over period of 3 days\n\nAutologous transplant: Subjects will receive standard melphalan 200mg/m\\^2 (100mg/m\\^2 day-2 and day-1) conditioning with autologous stem cell rescue","id":"EG002","otherNumAffected":3,"otherNumAtRisk":6,"seriousNumAffected":1,"seriousNumAtRisk":6,"title":"Cohort 3 Total Marrow Irradiation (TMI) 9Gy"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3,"numEvents":1},{"groupId":"EG001","numAffected":1,"numAtRisk":3,"numEvents":1},{"groupId":"EG002","numAffected":1,"numAtRisk":6,"numEvents":1}],"term":"Mucositis"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":3,"numEvents":1},{"groupId":"EG002","numAffected":1,"numAtRisk":6,"numEvents":1}],"term":"Nausea"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":3,"numEvents":0},{"groupId":"EG002","numAffected":1,"numAtRisk":6,"numEvents":1}],"term":"Diarrhea"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Metastatic prostate cancer(3GY) Progressive myeloma (6Gy and 9Gy)","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3,"numEvents":1},{"groupId":"EG001","numAffected":1,"numAtRisk":3,"numEvents":1},{"groupId":"EG002","numAffected":1,"numAtRisk":6,"numEvents":1}],"term":"Death"}],"timeFrame":"1 year"}